Lives of over 40 million Americans could be positively affected
A recent report from the Pharmaceutical Research and Manufacturers of America (PhRMA) found America’s biopharmaceutical companies are developing about 130 new medicines for the millions of patients affected by respiratory diseases.
All these medicines and others in development are currently awaiting review by the U.S. Food and Drug Administration (FDA) or in clinical trials:
- 54 medicines for asthma: The most common chronic condition among children in the United States, with more than 6 million children and 20 million adults affected
- 39 medicines for COPD: Affecting approximately 16 million Americans, these medicines also include treatments for emphysema and chronic bronchitis
- 12 medicines for allergies with respiratory symptoms: The sixth-leading cause of chronic illness in the United States. Common allergens include peanuts, dust mites and tree pollen
Millions of Americans suffer from respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). Together, these two diseases affect the day-to-day lives of over 40 million patients in the United States. Furthermore, respiratory allergies affect 10 percent of children under the age of 18. Not only do these diseases impact day-to-day functioning, but they can also be life-threatening.
The 130 medicines in development by America’s biopharmaceutical companies represent critical advances in our understanding of respiratory illnesses and in improving quality of life for millions of Americans. To learn more about these potential new treatments, view the full report here.